MedTrace Logo

Recurrence Risk Factors of Early-Stage Hepatocellular Carcinoma After Radio Frequency Ablation

NCT02046356 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 139

Last updated 2020-10-26

No results posted yet for this study

Summary

The aim was to investigate the efficacy of radiofrequency ablation (RFA) with a multiple-electrode switching system (MESS) in the treatment of early hepatocellular carcinoma (HCC) and to evaluate the patterns and risk factors of intrahepatic recurrence of HCC after RFA.

Conditions

Interventions

PROCEDURE

MESS-RFA

Sponsors & Collaborators

  • Southwest Hospital, China

    collaborator OTHER

  • Yunhua Tan

    lead OTHER

Principal Investigators

  • Yunhua Tan · Southwest Hospital, China

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-01-31
Primary Completion
2015-01-31
Completion
2020-12-31

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02046356 on ClinicalTrials.gov